No connection

Search Results

ABUS vs AMN

ABUS
Arbutus Biopharma Corporation
BEARISH
Price
$4.53
Market Cap
$872.0M
Sector
Healthcare
AI Confidence
85%
AMN
AMN Healthcare Services, Inc.
BEARISH
Price
$20.49
Market Cap
$787.1M
Sector
Healthcare
AI Confidence
78%

Valuation

P/E Ratio
ABUS
--
AMN
--
Forward P/E
ABUS
-27.41
AMN
30.31
P/B Ratio
ABUS
11.38
AMN
1.22
P/S Ratio
ABUS
61.92
AMN
0.29
EV/EBITDA
ABUS
-29.91
AMN
7.87

Profitability

Gross Margin
ABUS
-79.23%
AMN
29.37%
Operating Margin
ABUS
-727.31%
AMN
1.33%
Profit Margin
ABUS
-237.88%
AMN
-10.14%
ROE
ABUS
-38.52%
AMN
-35.9%
ROA
ABUS
-14.94%
AMN
1.17%

Growth

Revenue Growth
ABUS
-33.2%
AMN
-7.7%
Earnings Growth
ABUS
--
AMN
321.3%

Financial Health

Debt/Equity
ABUS
0.05
AMN
1.37
Current Ratio
ABUS
15.73
AMN
1.05
Quick Ratio
ABUS
15.52
AMN
0.94

Dividends

Dividend Yield
ABUS
--
AMN
--
Payout Ratio
ABUS
0.0%
AMN
0.0%

AI Verdict

ABUS BEARISH

ABUS exhibits severe financial distress signals with a Piotroski F-Score of 0/9, indicating extreme weakness in operational and financial health. The company reports massive negative margins, declining revenue, and unprofitable operations, with no meaningful cash flow or profitability. While the low debt-to-equity ratio and high current ratios suggest strong liquidity, they are likely inflated by non-operational cash reserves. The absence of a Graham Number and intrinsic value estimate reflects a lack of sustainable earnings, and the stock trades at a premium valuation despite deteriorating fundamentals. Analysts offer no consensus, and insider activity is neutral, reinforcing a lack of confidence.

Strengths
High current and quick ratios (15.73 and 15.52) indicate strong short-term liquidity
Low debt-to-equity ratio (0.05) suggests minimal leverage risk
Recent 1-year return of +34.4% shows strong price momentum despite fundamentals
Risks
Piotroski F-Score of 0/9 signals severe financial distress and operational failure
Negative profit margins (up to -237.88%) and declining revenue (-33.20% YoY) indicate deteriorating business model
No operating cash flow or free cash flow data available, raising concerns about sustainability
AMN BEARISH

The company exhibits severe financial distress with a Piotroski F-Score of just 2/9, indicating weak fundamental health. Despite recent earnings surprises and short-term EPS growth, the business is unprofitable (negative profit margin and ROE), leveraged (Debt/Equity of 1.37), and has declining revenues. Valuation metrics like a high Forward P/E of 30.31 and low Price/Sales of 0.29 reflect inconsistent pricing signals, while the stock has lost over 70% of its value in the past five years. The absence of an Altman Z-Score due to insufficient data further raises concerns about financial stability.

Strengths
Consistently beats earnings estimates with an average surprise of over 90% in the last four quarters
Recent quarterly EPS growth (Q/Q) of +30.0% shows potential operational improvement
Operating margin remains positive at 1.33% despite overall net losses
Risks
Piotroski F-Score of 2/9 signals severe financial weakness and high risk of continued deterioration
Negative profit margin (-10.14%) and ROE (-35.90%) indicate persistent unprofitability and poor capital efficiency
Revenue declining YoY by 7.70%, reflecting shrinking top-line and potential market share loss

Compare Another Pair

ABUS vs AMN: Head-to-Head Comparison

This page compares Arbutus Biopharma Corporation (ABUS) and AMN Healthcare Services, Inc. (AMN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile